

# Rita Vanbever

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2770541/publications.pdf>

Version: 2024-02-01

44  
papers

2,488  
citations

257450

24  
h-index

233421

45  
g-index

46  
all docs

46  
docs citations

46  
times ranked

2602  
citing authors

#	ARTICLE	IF	CITATIONS
1	Delivery strategies for sustained drug release in the lungs. <i>Advanced Drug Delivery Reviews</i> , 2014, 75, 81-91.	13.7	298
2	Formulation and physical characterization of large porous particles for inhalation. <i>Pharmaceutical Research</i> , 1999, 16, 1735-1742.	3.5	285
3	Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. <i>Journal of Controlled Release</i> , 2001, 70, 329-339.	9.9	266
4	Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. <i>Journal of Controlled Release</i> , 2004, 96, 233-244.	9.9	129
5	Aerosolization properties, surface composition and physical state of spray-dried protein powders. <i>Journal of Controlled Release</i> , 2004, 99, 357-367.	9.9	111
6	Fate of nanomedicines in the lungs. <i>Current Opinion in Colloid and Interface Science</i> , 2011, 16, 246-254.	7.4	103
7	Preclinical models for pulmonary drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 1231-1245.	5.0	101
8	Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. <i>Pharmaceutical Research</i> , 1999, 16, 555-561.	3.5	96
9	Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2004, 286, L1002-L1008.	2.9	91
10	Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1 $\alpha$ - <sup>34</sup> ) from rat lungs. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 1241-1252.	3.3	75
11	PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. <i>Journal of Controlled Release</i> , 2014, 187, 91-100.	9.9	72
12	The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. <i>Immunology</i> , 2007, 122, 316-325.	4.4	67
13	Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 839-844.	4.3	62
14	PEGylation of paclitaxel largely improves its safety and anti-tumor efficacy following pulmonary delivery in a mouse model of lung carcinoma. <i>Journal of Controlled Release</i> , 2016, 239, 62-71.	9.9	62
15	SPECT-CT Comparison of Lung Deposition using a System combining a Vibrating-mesh Nebulizer with a Valved Holding Chamber and a Conventional Jet Nebulizer: a Randomized Cross-over Study. <i>Pharmaceutical Research</i> , 2017, 34, 290-300.	3.5	59
16	Comparison of particle sizing techniques in the case of inhalation dry powders. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 2032-2041.	3.3	55
17	Sirtuin inhibition attenuates the production of inflammatory cytokines in lipopolysaccharide-stimulated macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2012, 420, 857-861.	2.1	47
18	Sustained release of insulin from insoluble inhaled particles. <i>Drug Development Research</i> , 1999, 48, 178-185.	2.9	46

#	ARTICLE	IF	CITATIONS
19	Confocal imaging of rat lungs following intratracheal delivery of dry powders or solutions of fluorescent probes. <i>Journal of Controlled Release</i> , 2002, 83, 331-341.	9.9	40
20	Fate of PEGylated antibody fragments following delivery to the lungs: Influence of delivery site, PEG size and lung inflammation. <i>Journal of Controlled Release</i> , 2018, 272, 62-71.	9.9	38
21	Mucosal and Systemic Immune Responses to Mycobacterium tuberculosis Antigen 85A following Its Co-Delivery with CpG, MPLA or LTB to the Lungs in Mice. <i>PLoS ONE</i> , 2013, 8, e63344.	2.5	34
22	Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 84, 40-48.	4.3	28
23	Protein Engineering Strategies for Improved Pharmacokinetics. <i>Advanced Functional Materials</i> , 2021, 31, 2101633.	14.9	28
24	PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab <sup>™</sup> antibody fragment after pulmonary delivery in three different species. <i>International Journal of Pharmaceutics</i> , 2017, 521, 120-129.	5.2	25
25	Minimal amounts of dipalmitoylphosphatidylcholine improve aerosol performance of spray-dried temocillin powders for inhalation. <i>International Journal of Pharmaceutics</i> , 2015, 495, 981-990.	5.2	24
26	Analysis of sialoadhesin expression on mouse alveolar macrophages. <i>Immunology Letters</i> , 2009, 124, 77-80.	2.5	20
27	Activity of Antibiotics against Staphylococcus aureus in an <i>In Vitro</i> Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	20
28	Encapsulation of a CpG oligonucleotide in cationic liposomes enhances its local antitumor activity following pulmonary delivery in a murine model of metastatic lung cancer. <i>International Journal of Pharmaceutics</i> , 2021, 600, 120504.	5.2	19
29	Production and characterization of a PEGylated derivative of recombinant human deoxyribonuclease I for cystic fibrosis therapy. <i>International Journal of Pharmaceutics</i> , 2017, 524, 159-167.	5.2	18
30	Synthesis and In Vitro Evaluation of Polyethylene Glycol-Paclitaxel Conjugates for Lung Cancer Therapy. <i>Pharmaceutical Research</i> , 2016, 33, 1671-1681.	3.5	16
31	Production, purification and biological characterization of mono-PEGylated anti-IL-17A antibody fragments. <i>International Journal of Pharmaceutics</i> , 2013, 454, 107-115.	5.2	15
32	Nicotinamide enhances apoptosis of G(M)-CSF-treated neutrophils and attenuates endotoxin-induced airway inflammation in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2011, 300, L354-L361.	2.9	14
33	Biodistribution and elimination pathways of PEGylated recombinant human deoxyribonuclease I after pulmonary delivery in mice. <i>Journal of Controlled Release</i> , 2021, 329, 1054-1065.	9.9	14
34	Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum. <i>Clinical Science</i> , 2018, 132, 1439-1452.	4.3	13
35	Performance-driven, pulmonary delivery of systemically acting drugs. <i>Drug Discovery Today: Technologies</i> , 2005, 2, 39-46.	4.0	10
36	PEGylation of Anti-Sialoadhesin Monoclonal Antibodies Enhances Their Inhibitory Potencies without Impairing Endocytosis in Mouse Peritoneal Macrophages. <i>Bioconjugate Chemistry</i> , 2009, 20, 295-303.	3.6	9

#	ARTICLE	IF	CITATIONS
37	Cationic Nanoliposomes Are Efficiently Taken up by Alveolar Macrophages but Have Little Access to Dendritic Cells and Interstitial Macrophages in the Normal and CpG-Stimulated Lungs. <i>Molecular Pharmaceutics</i> , 2019, 16, 2048-2059.	4.6	9
38	Safety evaluation of pulmonary influenza vaccination in healthy and "asthmatic" mice. <i>Vaccine</i> , 2008, 26, 2360-2368.	3.8	8
39	PEGylation of recombinant human deoxyribonuclease I decreases its transport across lung epithelial cells and uptake by macrophages. <i>International Journal of Pharmaceutics</i> , 2021, 593, 120107.	5.2	7
40	PEGylation of Recombinant Human Deoxyribonuclease I Provides a Long-Acting Version of the Mucolytic for Patients with Cystic Fibrosis. <i>Advanced Therapeutics</i> , 2021, 4, 2000146.	3.2	7
41	The Inhibitory Potencies of Monoclonal Antibodies to the Macrophage Adhesion Molecule Sialoadhesin Are Greatly Increased Following PEGylation. <i>Bioconjugate Chemistry</i> , 2008, 19, 2088-2094.	3.6	5
42	Needle-free iontophoresis-driven $\beta^2$ -adrenergic sweat rate test. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 407-415.	0.7	3
43	Production and characterization of mono-PEGylated alpha-1 antitrypsin for augmentation therapy. <i>International Journal of Pharmaceutics</i> , 2022, 612, 121355.	5.2	3
44	Preclinical evaluation of topically-administered PEGylated Fab <sup>™</sup> lung toxicity. <i>International Journal of Pharmaceutics: X</i> , 2019, 1, 100019.	1.6	2